Author

Damjana Bogatic

Observed names: D Bogatic, D. Bogatic

Institutions: Basil Hetzel Institute, Queen Elizabeth Hospital, Adelaide University, The University of Adelaide

Observed institutions: Royal Adelaide Hospital, Basil Hetzel Institute, Queen Elizabeth Hospital, Adelaide University, The University of Adelaide

ORCID: 0000-0001-9207-563X

Observed ORCID: 0000-0001-9207-563X

OpenAlex ID: A5071481733

Systematic review: microbial manipulation as therapy for primary sclerosing cholangitis

2022 · Damjana Bogatic, Robert V. Bryant, et al. · Alimentary Pharmacology & Therapeutics · 19

Frequent Dietetic Involvement Enhances Adherence and Clinical Outcomes of Exclusive Enteral Nutrition in Adults With Crohn's Disease

2025 · Matthew K. W. Chu, Alice S. Day, et al. · JGH Open · 5

PDF

High rates of treatment stage migration for early hepatocellular carcinoma and association with adverse outcomes: An Australian multicenter study

2022 · Kee Fong Loo, Richard J Woodman, et al. · JGH Open · 5

PDF

Intestinal Ultrasound Adds Diagnostic Value and Safety to a Dietitian‐Led Clinic for Disorders of Gut–Brain Interaction

2026 · R. M. Mathias, S. L. Plush, et al. · JGH Open · 1

Intestinal ultrasound reliably predicts fecal loading in patients with ulcerative colitis

2026 · Ryan Michael Mathias, Damjana Bogatic, et al. · Journal of Crohn s and Colitis · 1

Letter: Dose and Donor Matter—Determining the Optimal Strategy for Faecal Microbiota Transplantation in Clostridioides difficile Infection

2026 · D. Bogatic, S. P. Costello, et al. · Alimentary Pharmacology & Therapeutics · 1

OP15 Faecal microbiota transplantation for active Crohn’s disease: The MIRO (Microbial Restoration) randomised placebo-controlled trial.

2026 · S Fehily, E K Wright, et al. · Journal of Crohn s and Colitis · 1

729 Faecal Microbiota Transplantation for Active Crohn’s Disease: the Miro (microbial Restoration) Randomised Placebo-controlled Trial.

2026 · Sasha R. Fehily, Emily K. Wright, et al. · Gastrointestinal Endoscopy

729 Faecal Microbiota Transplantation for Active Crohn’s Disease: the Miro (microbial Restoration) Randomised Placebo-controlled Trial.

2026 · Sasha R. Fehily, Emily K. Wright, et al. · Gastroenterology

P1131 A randomised placebo-controlled dietary advice trial of the Four Strategies to SUlphide Reduction (4-SURE) diet in adults with mild-moderately active ulcerative colitis

2026 · A Day, L Portmann, et al. · Journal of Crohn s and Colitis

PDF

Balancing costs and care: evaluating the need for novel therapies for immune‐mediated inflammatory diseases in Australia

2025 · Damjana Bogatic, Miles P. Sparrow, et al. · Internal Medicine Journal

Editorial: Is Disease Clearance the Target in Ulcerative Colitis or a Stride Too Far?

2025 · R. M. Mathias, D. Bogatic, et al. · Alimentary Pharmacology & Therapeutics

PDF

P0735 Early dietetic assessment predicts clinical efficacy of Exclusive Enteral Nutrition in adults with Crohn’s disease

2025 · M Chu, A S Day, et al. · Journal of Crohn s and Colitis

PDF

Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease

2024 · D. Bogatic, R. V. Bryant · Alimentary Pharmacology & Therapeutics

PDF

Letter: Microbial manipulation for primary sclerosing cholangitis‐associated inflammatory bowel disease—hope on the horizon

2024 · D. Bogatic, R. V. Bryant · Alimentary Pharmacology & Therapeutics

PDF

Cover Image

2022 · Damjana Bogatic, Robert V. Bryant, et al. · Alimentary Pharmacology & Therapeutics

Works count: 16

Citation count: 33

H-index: 3

I10-index: 1